BUZZ-Hikma: top of the FTSE 100 on BAML upgrade
** Hikma rises 3 pct after BAML upgrades to "buy" from "neutral"
** Says it sees generous synergies from Roxane Laboratories acquisition; expects co to shut either its own or Roxane's US generics manufacturing plant
** Adds minimal colour on current pipeline but some large opportunities expected - sees $725-775m revenues in FY17
** Top riser on FTSE 100
(RM (LSE: RM.L - news) : alasdair.pal.thomsonreuters.com@reuters.net)